for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CORRECTED-BRIEF-Array Biopharma, Pierre Fabre say Columbus phase 3 study met primary endpoint

(Corrects to add dropped words ‘met primary endpoint’ in headline)

Sept 26 (Reuters) - Array Biopharma Inc :

* Global regulatory submissions planned for 2017

* Array Biopharma and Pierre Fabre announce columbus phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma met primary endpoint

* Generally well-tolerated and safety profile overall consistent with prior encorafenib plus binimetinib clinical trial results Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up